US OTC Monograph Reform's Early Results Could Be Label Orders From FDA, Wait And See For Industry

With much of FDA's work currently focused on the COVID-19 pandemic, the agency has limited resources available to implement monograph changes authorized by recent legislation. Drug firms awaited a monograph overhaul with expectations for success where they previously failed, but they need FDA's guidance to succeed.

 Stop Wait Go Glossy Button, Vector illustration

The earliest results of overhauling the program responsible for most OTC drugs available in the US likely will be regulatory orders for label changes for increasing safe use of some products and confusion from firms about navigating the revamped system.

Potential opportunities for adding ingredients, indications and dosage forms to the numerous product categories within the Food and Drug Administration's...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from International

More from Geography